- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04973072
The Effect of Small Wins on Body Fat Loss
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study, which spans 24 weeks (12 treatment, 12 post-treatment), aims to compare the effectiveness of 2 financial incentive structures: smaller rewards for achieving intermediate goals vs. a large reward for achieving an overall goal - on weight loss. Male Singaporeans or Permanent Residents between the ages of 25 and 60 will be recruited. Participants must be healthy and have a body mass index (BMI) of between 23 and 27.5, and own and use a smartphone or tablet. Participants will be given an individual-tailored percentage body fat (PBF) goal and will be blinded from the presence of different treatment conditions and randomly assigned to one of the three conditions for 12 weeks:
- Control group. Participants will receive only participation fees.
- One large reward treatment. Participants will be awarded S$X for reaching the PBF goal at the end of 12 weeks.
- Small wins treatment. Participants in the Small wins treatment condition will also be given 3 triweekly intermediate goals (IGs). Specifically, given the PBF goal, the PBF Loss Target (LT) is the difference between the initial PBF measured at the first visit and the goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. The cash rewards that participants will receive are capped by S$X and depend on which IGs participants achieve and whether participants maintain their progress at the end of the 12 weeks.
All participants will be given an individual-tailored 12-week percentage body fat (PBF) goal. The formula for this goal will be set in consultation with medical and fitness professionals (including certified doctors and fitness trainers) to ensure that it is safe, challenging, and achievable. The base formula, which assumes a 5% weight loss as is often defined to be the medically significant level, is:
(P* W - x*5%*W)/(95%*W)
where P is PBF at baseline (week 1), W is body mass in kg at baseline, P*W is their body fat mass at baseline, and x, ranging between 0% and 100%, is the parameter that is set in consultation with professionals. At 100%, it implies that all 5% in weight loss is from fat, vice versa.
Because P and W differ between most persons, the formula tailors a different goal to each research subject. The formula is meant to be flexible toward each individual participant's baseline weight and body fat percent. Leveraging the 5% weight loss target, the investigators determined the expected percentage of this weight that is lost as fat, knowing that weight loss includes not only fat loss but also other components such as water loss. In previous studies, for 1 kg loss in weight, on average, 78.8% came from body fat. Hence, the investigators have targeted 80% of weight loss from the participants to come from body fat.
To examine changes in health, objective measurements will be made during scheduled participant visits on Weeks 1, 12, and 24. Measures include height, weight, waist circumference, and PBF. Each participant will also be given a free digital scale for personal use from home. Their weight and PBF data from the scale will be synchronized to a mobile application. The investigators will retrieve with the participant's consent to examine changes throughout the study's duration.
There are a total of 3 scheduled visits. The first in Week 1 allows baseline measures to be determined. During the first visit, the participants will be provided with a Weight Loss Brochure to warn against the harmful effects of excessive weight loss. The second visit in Week 12 marks the end of the treatment and allows treatment effects to be investigated. The last visit in Week 24 checks for post-treatment effects. During all 3 visits, the participants will also complete a Health Risk Assessment Survey. This survey should take no longer than 10 minutes to complete, and the research team will be physically present to assist the participants with it if so required.
Due to the uncertainty of the pandemic, the investigators may hold the second and/or the third research visits virtually (or at least provide an online option) to avoid large gatherings if necessary. For each virtual research visit, the research team will contact the participants through a video call, during which participants will step on the weighing scales and show the readings to the team. If a research visit is held online, the participation fee/rewards will be sent electronically. The research team will still hold physical meetings for those who experience technical difficulties.
To let the participants track their PBF progress, every participant would be given a digital scale for their keeping even after the research has concluded. Referring to the Health Products Act (HPA), this scale would not be defined as a "medical device." The digital scale serves simply, as would a conventional scale, to inform the user on some bodily metric. It does not attempt to make any medical judgment or recommendation for the user. The research team has done testing on the digital scale and is satisfied with the precision of the device. The participants are expected to weigh-in on the scales weekly from home at their convenience. In the middle of each of the 12 weeks (e.g., Wednesday or Thursday), an automated email will be sent to the participants reminding the participants to do so by the end of the week (Sunday). Non-compliance will not be penalized, but participants are strongly encouraged to weigh-in. The following is the complete list of data that the participants will access from the scale's mobile application. The researchers, with the participants' consent, will also retrieve this data for analysis: 1. Basal metabolism rate; 2. BMI; 3. Bone mass; 4. Metabolic age; 5. Muscle mass; 6. PBF; 7. Skeletal muscle weight ratio; 8. Subcutaneous fat; 9. Total body water; 10. Visceral fat; 11. Weight
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ta-Cheng Huang, PhD
- Phone Number: +6566012086
- Email: tchuang@nus.edu.sg
Study Contact Backup
- Name: Aidas Masiliunas, PhD
- Email: gaiam@nus.edu.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- National University of Singapore
-
Contact:
- Ta-Cheng Huang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Singaporeans or PRs
- Male
- Between the ages of 25 and 60
- Body mass index (BMI) of between 23 and 27.5
- Own and use a smartphone or tablet
Exclusion Criteria:
- Currently participating in any other research program focused on physical activity or weight loss. Note: exercise or education programs (e.g. gym membership, diabetes education class) do not count as research programs.
- Have any reasons why they would not be able to complete a 24-week research program focused on improving health (e.g., plan to move to another country)
- Have a serious medical condition, including one or more of the following conditions: High blood pressure (hypertension), High cholesterol (Hyperlipidaemia), Heart attack (Myocardial infarction), Heart failure, Stroke (Cerebrovascular disease), Chronic obstructive pulmonary disease (COPD), Kidney disease, and Diabetes (Type 2).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Participants in this arm will not receive any intervention.
|
|
Experimental: One large reward
Participants in this arm will receive S$300 if they reach the PBF goal at the end of 12 weeks.
|
Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
|
Experimental: Small wins
Participants in this arm will receive cash rewards capped by S$300, depending on which intermediate goals they reach and the PBF at the end of the 12 weeks.
|
The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks.
Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal.
Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT.
Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal.
Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT.
At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whether reaching the prescribed PBF goal
Time Frame: At the end of the 12 weeks
|
This is a binary variable, which is 1 if the participant reaches the prescribed PBF goal, and 0 otherwise
|
At the end of the 12 weeks
|
Whether maintaining what has achieved in the post-treatment period
Time Frame: At the end of the 24 weeks
|
This is a binary variable, which is 1 if the participant loses more fat in the post-treatment period than in the intervention period, and 0 otherwise
|
At the end of the 24 weeks
|
Achievement Percentage
Time Frame: At the end of the 12 weeks
|
A percentage of the change in PBF from the predetermined change in PBF
|
At the end of the 12 weeks
|
Weekly Achievement Percentage
Time Frame: Through the study completion (24 weeks)
|
A percentage of the change in PBF from the predetermined change in PBF
|
Through the study completion (24 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Noah Lim, PhD, The Global Asia Institute, The National University of Singapore
- Principal Investigator: Alessandro Del Ponte, PhD, Institution for Social and Policy Studies, Yale University
- Principal Investigator: Ta-Cheng Huang, PhD, The Global Asia Institute, The National University of Singapore
- Principal Investigator: Aidas Masiliunas, PhD, The Global Asia Institute, The National University of Singapore
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NUS-IRB-2021-48
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Children's Hospital Los AngelesUniversity of Southern California; Tufts Medical CenterRecruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
National Taiwan University HospitalCompleted
-
University of California, San FranciscoNational Institutes of Health (NIH)CompletedModerately Overweight IndividualsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
Clinical Trials on One large reward treatment
-
Ruhr University of BochumCompleted
-
Florida International UniversityNational Institute of Mental Health (NIMH)CompletedConduct Disorder | Oppositional Defiant DisorderUnited States
-
Ruhr University of BochumCompletedPsychological Distress | Psychology, PositiveGermany
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
VA Office of Research and DevelopmentCompletedStroke | Aphasia | Dyslexia, AcquiredUnited States
-
Virginia Polytechnic Institute and State UniversityNational Institute of Mental Health (NIMH)CompletedAnxiety Disorders | Specific PhobiaUnited States
-
Dentsply InternationalWellspect HealthCareCompletedIntermittent Urethral CatheterizationSweden
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Completed
-
M.D. Anderson Cancer CenterCompleted
-
Virginia Polytechnic Institute and State UniversityNational Institute of Mental Health (NIMH)CompletedAnxiety Disorders | Phobic DisordersUnited States, Sweden